- Home
- PBYI vs PLX Comparison
PBYI vs PLX Comparison
Compare PBYI & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- PLX
- Stock Information
- Founded
- PBYI 2010
- PLX 1993
- Country
- PBYI United States
- PLX United States
- Employees
- PBYI N/A
- PLX N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PBYI Health Care
- PLX Health Care
- Exchange
- PBYI Nasdaq
- PLX Nasdaq
- Market Cap
- PBYI 237.2M
- PLX 204.9M
- IPO Year
- PBYI N/A
- PLX 1998
- Fundamental
- Price
- PBYI $5.41
- PLX $2.42
- Analyst Decision
- PBYI Strong Buy
- PLX Strong Buy
- Analyst Count
- PBYI 1
- PLX 1
- Target Price
- PBYI $7.00
- PLX $15.00
- AVG Volume (30 Days)
- PBYI 511.9K
- PLX 869.9K
- Earning Date
- PBYI 11-06-2025
- PLX 11-13-2025
- Dividend Yield
- PBYI N/A
- PLX N/A
- EPS Growth
- PBYI 434.29
- PLX N/A
- EPS
- PBYI 0.97
- PLX 0.08
- Revenue
- PBYI $238,062,000.00
- PLX $61,948,000.00
- Revenue This Year
- PBYI N/A
- PLX $14.53
- Revenue Next Year
- PBYI N/A
- PLX $75.77
- P/E Ratio
- PBYI $5.56
- PLX $31.06
- Revenue Growth
- PBYI 8.63
- PLX 62.79
- 52 Week Low
- PBYI $2.32
- PLX $1.01
- 52 Week High
- PBYI $6.07
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- PBYI 65.34
- PLX 60.70
- Support Level
- PBYI $5.11
- PLX $2.31
- Resistance Level
- PBYI $5.42
- PLX $2.61
- Average True Range (ATR)
- PBYI 0.25
- PLX 0.13
- MACD
- PBYI 0.06
- PLX -0.02
- Stochastic Oscillator
- PBYI 75.36
- PLX 58.62
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.